Vaccine responsiveness is often reduced in older adults. Young, middle-aged, and older adult participants (n=315) in the VITAL clinical trials were vaccinated with a quadrivalent influenza (QIV) booster, followed by a pneumococcal-conjugate (PCV13) vaccine, and then a SARS-CoV-2 mRNA-1273 vaccine. Booster QIV induced comparable H3N2 hemagglutination inhibition titers across age groups, but primary PCV13 and mRNA-1273 induced lower antibody concentrations in older adults. Humoral response persistence was shorter in older adults for all vaccines. Approximately 10% of participants, mainly older males, were low responders to multiple vaccines. This study identifies risk groups for low vaccine responsiveness.
Publisher
Nature Communications
Published On
Aug 04, 2024
Authors
Marieke van der Heiden, Sudarshan Shetty, Elske Bijvank, Lisa Beckers, Alper Cevirgel, Yannick van Sleen, Irina Tcherniaeva, Thierry Ollinger, Wivine Burny, Rob S. van Binnendijk, Marianne A. van Houten, Anne-Marie Buisman, Nynke Y. Rots, Josine van Beek, Debbie van Baarle
Tags
vaccine responsiveness
older adults
humoral response
QIV
PCV13
SARS-CoV-2
low responders
Related Publications
Explore these studies to deepen your understanding of the subject.
